Yunlyu Li

ORCID: 0009-0001-9511-438X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Complementary and Alternative Medicine Studies
  • Genetic and Kidney Cyst Diseases
  • Gastrointestinal motility and disorders
  • Diet and metabolism studies
  • Dialysis and Renal Disease Management
  • Gut microbiota and health
  • Renal and related cancers
  • Therapeutic Uses of Natural Elements
  • Renal Diseases and Glomerulopathies

Hong Kong Baptist University
2025

Ruijin Hospital
2010

Shanghai Institute of Hypertension
2010

Intestinal barrier dysfunction is widely observed in patients with irritable bowel syndrome (IBS) and significantly contributes to the persistence of IBS symptoms. The association between gut dysbiosis pathogenesis IBS, as well its connection intestinal dysfunction, has been established. However, precise roles bacteria inducing underlying mechanisms remain unclear. In present study, we showed that microbiota-derived lithocholic acid (LCA) positively associated biomarkers IBS-D. We found...

10.1101/2025.01.13.25320445 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2025-01-14

Podocyte injury plays a critical role in the progression of diabetic kidney disease (DKD), but underlying cellular and molecular mechanisms remain poorly understanding. MicroRNAs (miRNAs) can disrupt gene expression by inducing translation inhibition mRNA degradation, recent evidence has shown that miRNAs may play key many diseases. In this study, we identified miR-4645-3p global transcriptome profiling as one major downregulated high glucose-cultured podocytes. Moreover, whether DKD...

10.1096/fj.202300357rr article EN The FASEB Journal 2024-05-14

Objective: Several studies have reported a positive association between inflammation and chronic kidney disease (CKD), but this relation in hypertensive patients has not been well characterized. The aim of study was to investigate the relationship various markers, including osteopontin (OPN), matrix metalloproteinase-2 (MMP-2), tissue inhibitor metalloproteinase-1 (TIMP-1), high-sensitivity C-reactive protein (hsCRP), CKD patients. Design Method: 422 treated essential (62.3 % male; mean age...

10.1097/01.hjh.0000378679.70247.1e article EN Journal of Hypertension 2010-06-01
Coming Soon ...